Several other analysts have also weighed in on VYGR. ValuEngine lowered shares of Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Friday, July 28th. Stifel Nicolaus began coverage on shares of Voyager Therapeutics in a research report on Friday, July 28th. They set a buy rating and a $20.00 price target for the company. Cowen and Company restated a buy rating on shares of Voyager Therapeutics in a research report on Tuesday, August 8th. Zacks Investment Research lowered shares of Voyager Therapeutics from a hold rating to a sell rating in a research report on Friday, August 11th. Finally, Evercore ISI began coverage on shares of Voyager Therapeutics in a research report on Wednesday, August 16th. They set an outperform rating and a $12.00 price target for the company. Three investment analysts have rated the stock with a sell rating, one has given a hold rating and nine have issued a buy rating to the company. Voyager Therapeutics currently has an average rating of Hold and a consensus target price of $26.75.
Voyager Therapeutics (NASDAQ VYGR) traded up $1.24 during mid-day trading on Wednesday, reaching $13.59. 998,700 shares of the company’s stock traded hands, compared to its average volume of 232,510. Voyager Therapeutics has a 12-month low of $8.10 and a 12-month high of $25.99.
In related news, insider Bernard Ravina sold 5,490 shares of the stock in a transaction dated Tuesday, September 5th. The shares were sold at an average price of $10.00, for a total value of $54,900.00. Following the completion of the transaction, the insider now owns 17,157 shares in the company, valued at approximately $171,570. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 38,430 shares of company stock valued at $562,890 in the last quarter. 8.00% of the stock is currently owned by insiders.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. grew its position in Voyager Therapeutics by 57.7% in the 2nd quarter. Russell Investments Group Ltd. now owns 11,864 shares of the company’s stock valued at $106,000 after buying an additional 4,343 shares in the last quarter. JPMorgan Chase & Co. bought a new position in Voyager Therapeutics in the 3rd quarter valued at about $270,000. Hershey Trust Co. grew its position in Voyager Therapeutics by 163.0% in the 2nd quarter. Hershey Trust Co. now owns 14,394 shares of the company’s stock valued at $129,000 after buying an additional 8,921 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in Voyager Therapeutics in the 2nd quarter valued at about $143,000. Finally, Rhumbline Advisers grew its position in Voyager Therapeutics by 34.7% in the 2nd quarter. Rhumbline Advisers now owns 16,091 shares of the company’s stock valued at $144,000 after buying an additional 4,144 shares in the last quarter. Hedge funds and other institutional investors own 40.93% of the company’s stock.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
Receive News & Ratings for Voyager Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.